Biotricity Inc. (OTCQB: BTCY) announced its financial results for the third quarter of fiscal year 2025, ended December 31, 2024. The company reported record margins, record revenues, and record cashflows.
The fiscal third quarter demonstrated 21.7% year-over-year sales growth, along with improvements in all key operating metrics, including recurring technology fees, device sales, and gross margins. These results reflect the company's commitment to automation and operating efficiency.
Biotricity continues to leverage its AI-driven solutions and Biocore suite of products, which have contributed to over hundreds of thousands of atrial fibrillation diagnoses over the past two years. The company maintains a strong focus on cost control and expense reduction, making consistent progress towards positive cash flow and profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.